Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
Abstract: A process is provide for the preparation of compounds of formula (I) herein
comprising reacting a compound of formula (III), (IV) or (V)
wherein the variables are as defined in the specification. The reaction is conducted in the presence of −OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent.
Type:
Grant
Filed:
July 26, 2001
Date of Patent:
October 26, 2004
Assignee:
Pfizer Inc.
Inventors:
Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Keith Michael DeVries, Laurence James Harris, Philip Charles Levett, Joanna Teresa Negri, David James Rawson, Albert Shaw Wood
Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
Type:
Grant
Filed:
August 28, 2002
Date of Patent:
October 26, 2004
Assignee:
Pfizer Inc
Inventors:
Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
Abstract: This invention relates to compounds of the formula
and to pharmaceutically acceptable salts, prodrugs, and solvates thereof wherein X, Y, R1, R2, R3, R4, and R6 are as defined herein. The compounds of formula I are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I, methods of making the compounds, and to methods of treating bacterial and protozoal infections by administering the compounds.
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
October 26, 2004
Assignee:
Pfizer, Inc.
Inventors:
Takushi Kaneko, William Thomas McMillen
Abstract: Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.
Type:
Application
Filed:
May 4, 2004
Publication date:
October 21, 2004
Applicant:
Pfizer Inc
Inventors:
Dwayne Thomas Friesen, Scott Max Herbig, Ravi Mysore Shanker, James Blair West
Abstract: The method and system of the present invention is a Resource Forecasting Model (hereinafter “the RFM”). The RFM is a model of the Drug Development Process. More specifically, the RFM calculates Direct Project Resources for the development process of pharmaceutical drug Candidates, for a user-selected Forecast Period after initial discovery of the Candidates until final FDA regulatory approval thereof. The present invention provides a computer system with a database, a server, and a client. The client may be connected to the database and server via a direct connection, such as a local network, or via a web-based connection.
Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression.
Abstract: The invention provides a method for detecting RNA polymerase activity in a continuous-read manner. Specifically, the invention provides a method for detecting the de novo polymerase activity of the Hepatitis C virus (HCV) polymerase, NS5B, in a continuous-read manner. The invention also provides a method of screening for modulators of RNA polymerase activity. More specifically, the invention provides a method of screening for modulators of HCV NS5B activity.
Type:
Application
Filed:
November 13, 2003
Publication date:
October 21, 2004
Applicant:
Pfizer Inc.
Inventors:
Yoshihiko Yagi, Michael P. Sheets, Peter A. Wells, John A. Shelly, Roger A. Poorman, Dennis E. Epps, Aric G. Morgan
Abstract: The invention is directed to methods of treating asthma, COPD, allergic rhinitis, and infectious rhinitis by administering a first pharmaceutical agent including one or more compounds selected from the quarternary ammonium compounds of formulae I-V and a second pharmaceutical agent including one or more pharmaceutical agents selected from Adenosine A2a Receptor Agonists, D2-Dopamine Receptor Agonists, Phosphodiesterase Inhibitors (PDE's), corticosteroids, norepinephrine reuptake inhibitors, 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]-propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one, and pharmaceutically acceptable salts thereof, and non-quarternized antimuscarinic compounds.
Type:
Application
Filed:
April 13, 2004
Publication date:
October 21, 2004
Applicant:
Pfizer Inc
Inventors:
Ivan Michael Richards, Robert Everett Manning
Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
Type:
Application
Filed:
April 27, 2004
Publication date:
October 14, 2004
Applicant:
Pfizer Inc
Inventors:
Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
Abstract: The present invention relates to a therapeutic method comprising administering anti-IGF-IR antibodies, particularly human anti-IGF-IR antibodies to a subject for the treatment of certain disorders preferably in conjunction with administration of another therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment.
Type:
Application
Filed:
February 10, 2004
Publication date:
October 14, 2004
Applicant:
Pfizer Inc.
Inventors:
Bruce D. Cohen, Vahe Bedian, Mihail Obrocea, Jesus Gomez-Navarro, John D. Cusmano, Huifen F. Wang, Deborah J. Guyot, Kelly L. Page
Abstract: Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Type:
Application
Filed:
March 23, 2004
Publication date:
October 14, 2004
Applicant:
Pfizer Inc
Inventors:
Bruce M. Bechle, George C. Chang, Mary Didiuk, Jari I. Finneman, Ravi S. Garigipati, Ryan M. Kelley, David A. Perry, Roger B. Ruggeri
Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression.
Abstract: The subject invention relates to 4-phenyl-piperidine derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by an opioid receptor. The subject also particularly relates to using such derivatives to treat certain disease states, disorders and conditions, for example irritable bowel syndrome, drug addiction or dependency, including alcohol addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia and eating disorders, among numerous other disease states, disorders and conditions as more fully described herein.
Type:
Application
Filed:
January 22, 2004
Publication date:
October 14, 2004
Applicant:
Pfizer Inc
Inventors:
Stanton McHardy, Spiros Liras, Sara Guediche, Jotham W. Coe
Abstract: The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.
Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression.
Abstract: A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.
Type:
Grant
Filed:
August 17, 2000
Date of Patent:
October 12, 2004
Assignee:
Pfizer, Inc.
Inventors:
Michael P. DeNinno, Hiroko Masamune, Robert W. Scott